Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 3/20 | 0.63 |
| ▸ | PTGES | O14684 | 1/20 | 0.60 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.52 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.50 |
| ▸ | GCK | P35557 | 3/20 | 0.49 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.48 |
| ▸ | RARA | P10276 | 1/20 | 0.47 |
| ▸ | RARB | P10826 | 1/20 | 0.47 |
| ▸ | RARG | P13631 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31585829 | 1.00 | HCAR3 (0.63) | HCAR3PTGESKCNK3KCNK9GAA | |
| SCHEMBL5738920 | 0.88 | PTGES (0.59) | HCAR3PTGESKCNK3KCNK9GAA | |
| SCHEMBL28620384 | 0.87 | HCAR3 (0.53) | HCAR3PTGESKCNK3KCNK9GAA | |
| SCHEMBL26405652 | 0.86 | PTGES (0.57) | HCAR3PTGESKCNK3KCNK9GAA | |
| SCHEMBL30416204 | 0.84 | DEGS1 (0.60) | PTGESKCNK3KCNK9GAALMNA | |
| SCHEMBL5235614 | 0.84 | HCAR3 (0.52) | HCAR3PTGESGAATRPV1GCK | |
| SCHEMBL25383706 | 0.83 | PTGS1 (0.61) | PTGESKCNK3KCNK9GAALMNA | |
| Hydrochloric Acid SCHEMBL30415721 | 0.83 | DEGS1 (0.59) | PTGESKCNK3KCNK9GAALMNA | |
| SCHEMBL30354790 | 0.83 | PTGS1 (0.61) | PTGESKCNK3KCNK9GAALMNA | |
| SCHEMBL5233704 | 0.82 | HCAR3 (0.68) | HCAR3GAAGCKRARARARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051310-A1 | BENZAZEPINE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-02-13 | — | — | US | disclosed |
| EP-4056557-B1 | BENZAZEPINE DERIVATIVES USEFUL AS MEDICAMENTS | OTSUKA PHARMA CO LTD (JP) | 2023-11-22 | — | — | EP | disclosed |
| EP-4253367-A1 | NOVEL BENZAZEPINE SPIRO DERIVATIVE | Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) | 2023-10-04 | — | — | EP | disclosed |
| US-20230265073-A1 | BENZAZEPINE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-08-24 | — | — | US | disclosed |
| US-11673878-B2 | Benzazepine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-06-13 | — | — | US | disclosed |
| US-20210078976-A1 | BENZAZEPINE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-03-18 | — | — | US | disclosed |
| US-10889570-B2 | Benzazepine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-01-12 | — | — | US | disclosed |
| EP-3645513-A1 | BENZAZEPINE DERIVATIVES | Otsuka Pharmaceutical Co., Ltd. (JP) | 2020-05-06 | — | — | EP | disclosed |
| WO-2019004421-A1 | BENZAZEPINE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-01-03 | — | — | WO | disclosed |
| EP-0804440-B1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | WYETH CORP (US) | 2007-12-19 | — | — | EP | disclosed |
| EP-0811008-B1 | BICYCLIC BENZAZEPINE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | WYETH CORP (US) | 2003-10-01 | — | — | EP | disclosed |
| CN-1065244-C | Tricyclic benzazepine vasopressin antagonists | AMERICAN CYANAMID CO (US) | 2001-05-02 | — | — | CN | disclosed |
| CN-1061658-C | Tricyclic benzazepine vasopressin antagonists | AMERICAN CYANAMID CO (US) | 2001-02-07 | — | — | CN | disclosed |
| CN-1198746-A | Tricyclic benzazepine * vasopressin antagonists | AMERICAN CYANAMID CO (US) | 1998-11-11 | — | — | CN | disclosed |
| US-5654297-A | CONGESTIVE HEART FAILURE, CARDIOVASCULAR DISORDERS | AMERICAN CYANAMID COMPANY (US) | 1997-08-05 | — | — | US | disclosed |
| US-5612334-A | Tricyclic benzazepine vasopressin antagonists | AMERICAN CYANAMID COMPANY (US) | 1997-03-18 | — | — | US | disclosed |
| US-5610156-A | USED IN TREATING DISEASES CHARACTERIZED BY EXCESS RENAL REABSORPTION OF WATER | AMERICAN CYANAMID COMPANY (US) | 1997-03-11 | — | — | US | disclosed |
| WO-1996022293-A1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | AMERICAN CYANAMID COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
| WO-1996022294-A1 | BICYCLIC BENZAZEPINE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | AMERICAN CYANAMID COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
| US-5532235-A | TO TREAT EXCESS RENAL REABSORPTION | AMERICAN CYANAMID COMPANY (US) | 1996-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210078976-A1 | BENZAZEPINE DERIVATIVES | AVPR2, AVPR1A, AVPR1B | HCAR3 449/4885PTGES 1500/4885KCNK3 261/4885 |
| US-20230265073-A1 | BENZAZEPINE DERIVATIVES | AVPR2, AVPR1A, AVPR1B | HCAR3 449/4885PTGES 1500/4885KCNK3 261/4885 |
| US-11673878-B2 | Benzazepine derivatives | AVPR2, AVPR1A, AVPR1B | HCAR3 449/4885PTGES 1500/4885KCNK3 261/4885 |
| US-20250051310-A1 | BENZAZEPINE DERIVATIVES | AVPR2, AVPR1A, AVPR1B | HCAR3 742/4885PTGES 1533/4885KCNK3 228/4885 |
| US-10889570-B2 | Benzazepine derivatives | AVPR2, AVPR1A, AVPR1B | HCAR3 449/4885PTGES 1500/4885KCNK3 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.